Skip to main content
OpenTrials
Completed

NCT Number: NCT06404580

The Benefits of R Anastomotic Technique for Billroth-II Reconstruction With Braun Anastomosis During Totally Laparoscopic Distal Gastrectomy: a Propensity Score Matching Analysis

Between March 2019 and September 2022 in our centre, R anastomosis was performed on 123 patients undergoing TLDG for distal gastric cancer. A retrospective review of a prospectively collected database identified patients who underwent TLDG between January 2010 and September 2022. Patients who underwent R anastomosis were matched in a 1:1 ratio with patients who underwent conventional anastomosis using a propensity score based on age, sex, preoperative BMI, American Society of Anesthesiologists (ASA) score, and the history of abdominal surgery. Surgical and postoperative outcomes and clinicopathological data were analyzed for both groups.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

the Incidences of Clavien-Dindo Grade II or Higher Anastomotic Time

Age range

35 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, 225001, China

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • elective surgery for endoscopic and pathological diagnosis of malignant tumour of the gastric antrum or body with no distant metastases confirmed by multilayer spiral computed tomography;
  • patients who underwent B-II-B anastomosis during TLDG; and (3) patients who could be followed up postoperatively.

Exclusion criteria

(1) patients who had received preoperative neoadjuvant radiotherapy or chemotherapy; (2) patients undergoing emergency surgery; (3) the presence of other malignant tumours concurrently; and (4) patients who were lost to follow-up.

Treatment and study plan

R anastomosis

Procedure

R anastomosis

Primary outcomes

  1. the incidences of Clavien-Dindo grade II or higher

    Time frame: 2010-2022

    the incidences of Clavien-Dindo grade II or higher

  2. anastomotic time

    Time frame: 2010-2022

    anastomotic time

Sponsors and collaborators

Lead sponsor

Daorong Wang

Other

Registry information

Important dates

Study start
2019
Primary completion
2022
Study completion
2023
First posted
May 8, 2024
Registry last updated
May 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.